Vir Biotechnology, Inc.·4

May 25, 5:52 PM ET

MORE ROBERT J 4

4 · Vir Biotechnology, Inc. · Filed May 25, 2022

Insider Transaction Report

Form 4
Period: 2022-05-23
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-05-23+12,81012,810 total
    Exercise: $24.14From: 2023-05-23Exp: 2032-05-22Common Stock (12,810 underlying)
  • Award

    Common Stock

    2022-05-23+6,40542,435 total
Holdings
  • Common Stock

    (indirect: See footnote)
    486,111
Footnotes (1)
  • [F1]The shares are held by Alta Partners NextGen Fund I, L.P. (APNG 1). The reporting person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the reporting person may be deemed to beneficially own the shares held by APNG 1. However, the reporting person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION